Human Papillomavirus: Vaccination
(asked on 14th June 2018) - View Source
Question to the Department of Health and Social Care:
To ask Her Majesty's Government what is the Joint Committee on Vaccination and Immunisation's latest assessment of the proportion of cancers which are caused by vaccine-preventable types of human papillomavirus.
The Joint Committee on Vaccination and Immunisation (JCVI) published an interim statement on extending the human papillomavirus (HPV) vaccination to adolescent boys in July 2017. The interim statement and the following table set out the proportion of cancers attributable to HPV infection by disease, as modelled by Public Health England (PHE). A copy of the JCVI Interim Statement on Extending HPV Vaccination to Adolescent Boys is attached.
Cancer site (females) | High-risk HPV type (attribution fraction) |
Cervix | HPV16/18/31/33/45/52/58/other (35/39/51/56/59/68) (95.1%) |
Vulva | HPV16/18/33 (12.7%) |
Vagina | HPV16 (53.7%) |
Anus | HPV16/18/33 (77.0%) |
Oropharynx | HPV16 (24.7%) |
Oral cavity | HPV16/18 (1.1%) |
Larynx | HPV16/18 (1.9%) |
Cancer site (males) | High-risk HPV type (attribution fraction) |
Anus | HPV16/18/33 (77.0%) |
Penis | HPV16/18 (28.6%) |
Oropharynx | HPV16 (12.8%) |
Oral cavity | HPV16/18 (1.4%) |
Larynx | HPV16/18 (0.6%) |
Note:
Attributable fraction for high risk HPV types associated with cancer as modelled by PHE and based on International Agency for Research on Cancer reviews.
The JCVI most recently considered HPV vaccination on 6 June 2018, and the minutes of that meeting will be published on or before 18 July 2018.